The success of Sildenafil initially fueled a surge for pharma, but recent developments present a uncertain scenario for those considering a stake. Off-patent alternatives are eating into revenue, and continued patent https://kiarajgcm372197.bloggip.com/41597144/the-blue-pill-and-pharma-a-risky-investment